Koninklijke Philips (NYSE:PHG) Stock Rating Lowered by Wall Street Zen

Koninklijke Philips (NYSE:PHG - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Sunday.

PHG has been the topic of several other reports. BNP Paribas raised shares of Koninklijke Philips from a "neutral" rating to an "outperform" rating in a research report on Tuesday, February 25th. Sanford C. Bernstein upgraded shares of Koninklijke Philips from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 18th. Finally, UBS Group upgraded shares of Koninklijke Philips from a "neutral" rating to a "buy" rating in a research note on Thursday, February 20th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy".

Koninklijke Philips Trading Down 0.2%

PHG stock traded down $0.03 during trading on Friday, reaching $22.08. The company had a trading volume of 959,627 shares, compared to its average volume of 887,096. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.28 and a quick ratio of 0.79. Koninklijke Philips has a 52 week low of $20.61 and a 52 week high of $31.57. The business has a 50 day moving average of $23.75 and a 200 day moving average of $25.20. The company has a market cap of $20.75 billion, a P/E ratio of 51.34, a PEG ratio of 0.63 and a beta of 0.76.

Koninklijke Philips (NYSE:PHG - Get Free Report) last released its earnings results on Tuesday, May 6th. The technology company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.13. Koninklijke Philips had a return on equity of 10.97% and a net margin of 2.11%. The company had revenue of $4.31 billion during the quarter, compared to analysts' expectations of $4.10 billion. During the same quarter last year, the business posted $0.21 EPS. The firm's revenue for the quarter was down 1.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Koninklijke Philips will post 1.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Koninklijke Philips

Several institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its stake in shares of Koninklijke Philips by 20.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 8,856 shares of the technology company's stock valued at $223,000 after acquiring an additional 1,509 shares in the last quarter. ABC Arbitrage SA purchased a new position in Koninklijke Philips during the 4th quarter worth $902,000. Allworth Financial LP raised its position in Koninklijke Philips by 24.9% during the 4th quarter. Allworth Financial LP now owns 3,993 shares of the technology company's stock valued at $105,000 after purchasing an additional 797 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in shares of Koninklijke Philips by 1.3% in the 4th quarter. Sanctuary Advisors LLC now owns 59,213 shares of the technology company's stock worth $1,660,000 after buying an additional 778 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Koninklijke Philips during the 4th quarter worth $263,000. Institutional investors own 13.67% of the company's stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.